Patient Access Schemes

Patient Access Schemes

When assessing new drugs and treatments - to decide whether they represent good value for the NHS - the National Institute for Health and Care Excellence (NICE) looks at evidence on how well the treatment works compared with available alternatives, and the cost of treatment. 

Drugs or treatments that are expensive and do not have a significant benefit over existing treatments are unlikely to be approved by NICE for use in the NHS.  Patient access schemes are special ways Pharmaceutical companies can propose to enable patients to gain access to high costs drugs.

Drugs which receive a positive NICE appraisal, that have a patient access scheme attached, are commissioned on the basis that any patient access scheme is fully utilised and adhered to.

Where a patient access scheme exists it is vital that NHS bodies make full access to the scheme to secure maximum cost effectiveness of providing treatment. 

Each scheme is different and hence a good understanding of them will ensure they are used to their full potential.  Please click the link below to access a comprehensive list of current patient access schemes. 
Patient Access Schemes (December 2016)
NICE Patient Access Schemes Liaison Unit (PASLU)

Details of the NICE Patient Access Schemes Liaison Unit (PASLU) can be accessed via the link below.  PASLU is the part of the NICE Centre for Health Technology Evaluation that coordinates the review and evaluation of patient access schemes proposals and produces guidance to the Department of Health. 
NICE Patient Access Schemes Liaison Unit (PASLU)

Rate this page